Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant ProgramGlobeNewsWire • 09/24/24
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific MeetingGlobeNewsWire • 09/19/24
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 StudyBenzinga • 09/09/24
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual MeetingGlobeNewsWire • 09/05/24
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024GlobeNewsWire • 09/01/24
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024GlobeNewsWire • 09/01/24
Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion OpportunitiesSeeking Alpha • 08/13/24
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in FocusZacks Investment Research • 08/09/24
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese ParticipantsGlobeNewsWire • 06/17/24
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineGlobeNewsWire • 05/22/24
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle BiologyGlobeNewsWire • 05/17/24
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024GlobeNewsWire • 05/15/24
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A DayInvestors Business Daily • 05/13/24